The medical technology sector is facing a critical juncture as the Australian government's recent budget changes threaten to disrupt the growth and development of health startups. The Labor Party's overhaul of the capital gains tax (CGT) and research and development (R&D) tax incentive has sparked concern among industry bodies, who argue that these changes could hinder the progress of medical innovation in the country.
One of the key issues is the ten-year limit on the R&D tax incentive, which allows companies to receive refunds for losses incurred during the research and development phase. This limit is particularly problematic for health startups, as it takes significantly longer for them to bring products to market compared to other industries. The letter sent to Treasurer Jim Chalmers highlights that these companies typically spend years progressing through various stages, including discovery, pre-clinical development, evidence generation, clinical trials, regulatory approval, and manufacturing scale-up, before revenue generation becomes possible. As a result, the ten-year limit could severely impact their ability to access the necessary funding and support.
The removal of R&D 'supporting activities' from eligibility is another concern. Many health startups cannot afford to bring in-house the clinical, regulatory, and quality services required during their initial years. This limitation could put at risk Australia's world-class health and medical research support organizations, which play a crucial role in the development of medical technologies and drugs.
The CGT changes have also raised questions about the viability of high-risk research and development for medical technology businesses. The switch from a flat 50% CGT discount to a model tied to inflation, combined with the ten-year limit on the R&D incentive, could make many companies reconsider their long-term plans and whether staying in Australia is the right choice. This uncertainty is already causing issues, with companies making 'long-range' decisions about where to undertake clinical developments.
The impact of these changes extends beyond individual companies. Over the past ten years, biotechnology has become a significant export industry for Australia, supporting over 350,000 jobs across almost 3,000 organizations. The proposed changes could potentially hamper the development of Australian-made medical products and drugs, putting at risk the country's position in the global medical technology market.
The concerns are not limited to the medical technology sector alone. Shadow Treasurer Tim Wilson and Shadow Health Minister Anne Ruston have accused the Labor Party of failing to understand the negative impact of the budget changes on building Australia's future economy, including medical technology. They argue that the changes, combined with the government's slow response to the Health Technology Assessment Review, could result in Australia falling behind in access to new life-changing and life-saving medicines and medical technologies.
The Labor Party, however, remains confident in its approach. Treasurer Jim Chalmers is consulting with the tech sector and startups about carve-outs for the CGT changes, acknowledging the disproportionate impact on companies with a low-cost base. The government is also conducting consultations to inform a position paper and develop a second tranche of legislation on the implementation of the CGT changes.
Despite these efforts, the rapid pace of the legislation has fueled criticism. Business groups have demanded significant changes to the CGT overhaul, but Prime Minister Anthony Albanese has ruled out a 'long, drawn-out process that ends with fiddling around the edges of the status quo'.
In my opinion, the Australian government's budget changes could have far-reaching consequences for the medical technology sector. The impact on health startups, in particular, could be devastating, hindering their ability to bring life-saving innovations to market. It is crucial for the government to carefully consider the concerns raised by industry bodies and make the necessary adjustments to ensure the continued success of Australian companies in this vital sector. The future of medical innovation in Australia may depend on it.
